Published in Chemphyschem on April 06, 2010
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol (2015) 2.08
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization. Nat Mater (2015) 1.65
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm (2010) 1.05
Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging (2011) 1.04
Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials (2013) 1.03
Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening. Nanotechnology (2013) 0.97
Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors. Small (2012) 0.95
Particle platforms for cancer immunotherapy. Int J Nanomedicine (2013) 0.93
In silico vascular modeling for personalized nanoparticle delivery. Nanomedicine (Lond) (2012) 0.93
Proteomic analysis of serum opsonins impacting biodistribution and cellular association of porous silicon microparticles. Mol Imaging (2011) 0.92
Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. Cancer Lett (2012) 0.90
Silicon micro- and nanofabrication for medicine. Adv Healthc Mater (2013) 0.90
Degradation and biocompatibility of multistage nanovectors in physiological systems. J Biomed Mater Res A (2013) 0.90
Evaluation of cell function upon nanovector internalization. Small (2012) 0.87
Biocompatibility assessment of Si-based nano- and micro-particles. Adv Drug Deliv Rev (2012) 0.87
Activation of the inflammasome and enhanced migration of microparticle-stimulated dendritic cells to the draining lymph node. Mol Pharm (2012) 0.86
Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. Biomaterials (2013) 0.85
Multistage vector (MSV) therapeutics. J Control Release (2015) 0.84
Multifunctional to multistage delivery systems: The evolution of nanoparticles for biomedical applications. Chin Sci Bull (2012) 0.83
Multiscale patterning of a biomimetic scaffold integrated with composite microspheres. Small (2014) 0.82
The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation. Biomaterials (2014) 0.82
Porous silicon advances in drug delivery and immunotherapy. Curr Opin Pharmacol (2013) 0.81
Biodegradable nanoneedles for localized delivery of nanoparticles in vivo: exploring the biointerface. ACS Nano (2015) 0.81
Mechanism of erosion of nanostructured porous silicon drug carriers in neoplastic tissues. Nat Commun (2015) 0.80
Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs. Curr Drug Targets (2015) 0.80
Bacteriophage Associated Silicon Particles: Design and Characterization of a Novel Theranostic Vector with Improved Payload Carrying Potential. J Mater Chem B Mater Biol Med (2013) 0.80
Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors. Nanoscale (2014) 0.80
Cefazolin-loaded mesoporous silicon microparticles show sustained bactericidal effect against Staphylococcus aureus. J Tissue Eng (2014) 0.79
Gated Luminescence Imaging of Silicon Nanoparticles. ACS Nano (2015) 0.78
Low pressure mediated enhancement of nanoparticle and macromolecule loading into porous silicon structures. Mesoporous Biomater (2014) 0.77
Chemical patterning on preformed porous silicon photonic crystals: towards multiplex detection of protease activity at precise positions†Electronic supplementary information (ESI) available: SEM images, XPS result and more optical reflectivity data. See DOI: 10.1039/c4tb00281dClick here for additional data file. J Mater Chem B Mater Biol Med (2014) 0.77
Cell source determines the immunological impact of biomimetic nanoparticles. Biomaterials (2015) 0.77
Composite microsphere-functionalized scaffold for the controlled release of small molecules in tissue engineering. J Tissue Eng (2016) 0.76
Biomimetic carriers mimicking leukocyte plasma membrane to increase tumor vasculature permeability. Sci Rep (2016) 0.75
Angular Approach Scanning Ion Conductance Microscopy. Biophys J (2016) 0.75
Preparation, characterization, and cellular associations of silicon logic-embedded vectors. Methods Enzymol (2012) 0.75
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A (2008) 7.06
Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev (2004) 5.31
Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc (2005) 4.02
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Biomolecular screening with encoded porous-silicon photonic crystals. Nat Mater (2002) 3.13
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer (2006) 2.04
Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release (2005) 1.97
Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol (2006) 1.94
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials (2007) 1.60
A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device--a first-in-man study. Int J Radiat Oncol Biol Phys (2006) 1.48
The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J Biomech (2008) 1.46
Evaluation of mammalian cell adhesion on surface-modified porous silicon. Biomaterials (2006) 1.44
Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle. Br J Ophthalmol (2008) 1.22
Mesoporous silicon: a platform for the delivery of therapeutics. Expert Opin Drug Deliv (2007) 1.18
Recent advances in electron tomography: TEM and HAADF-STEM tomography for materials science and semiconductor applications. Microsc Microanal (2005) 1.02
Acute toxicity of intravenously administered microfabricated silicon dioxide drug delivery particles in mice: preliminary findings. Drugs R D (2005) 0.91
Digital microfluidics and delivery of molecular payloads with magnetic porous silicon chaperones. Dalton Trans (2007) 0.89
Micropatterning of porous silicon films by direct laser writing. Biotechnol Prog (2006) 0.87
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Clinical proteomics: written in blood. Nature (2003) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
The use of rodent models to investigate host-bacteria interactions related to periodontal diseases. J Clin Periodontol (2008) 2.21
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
Graphene films with large domain size by a two-step chemical vapor deposition process. Nano Lett (2010) 2.10
The TatA component of the twin-arginine protein transport system forms channel complexes of variable diameter. Proc Natl Acad Sci U S A (2005) 2.02
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochim Biophys Sin (Shanghai) (2008) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16
Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16
Design of bio-mimetic particles with enhanced vascular interaction. J Biomech (2009) 1.15
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
Laparoscopic treatment of splenic artery aneurysms. J Vasc Surg (2009) 1.13
E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater (2011) 1.12
Nanotechnology for breast cancer therapy. Biomed Microdevices (2009) 1.10
Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics (2010) 1.08
Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials (2012) 1.07
Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One (2012) 1.07
Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J (2005) 1.07
The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann Biomed Eng (2008) 1.07
Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget (2011) 1.06
Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett (2012) 1.06
Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small (2013) 1.05
Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging (2011) 1.04
Nanotechnology and tumor imaging: seizing an opportunity. Mol Imaging (2004) 1.04
Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials (2013) 1.03